Histamine H4 receptor : a Novel Drug Target For Immunoregulation and Inflammation / Holger Stark.

Frontmatter -- Contents -- Preface -- Chapter 1 The histamine H4 receptor story -- Chapter 2 Histamine H4 Receptor Ligands -- Chapter 3 Histamine Metabolism -- Chapter 4 Histamine Receptors and Inflammatory Cells -- Chapter 5 Histamine in Asthmatic and Fibrotic Lung Disorders -- Chapter 6 Histamine in Atopic Disorders: Atopic Dermatitis and Pruritus -- Chapter 7 Non-professional Histamine Producing Cells, Immune Responses and Autoimmunity -- Chapter 8 Histamine in Cancer -- Chapter 9 Non Receptor-mediated Histamine Actions -- Chapter 10 Perspectives in H4R Research and Therapeutic Exploitation -- List of Figures -- List of Tables -- Index

Open Access unrestricted online access star

https://purl.org/coar/access_right/c_abf2

H4 R is the newest member of the histamine receptor family, which was discovered about twelve years ago. It is considered a very promising drug target. The effort to improve the pharmacokinetic properties of the currently available H4 R ligands is reflected in a steadily growing number of scientific publications and patent applications. Preclinical data strongly confirms the need for novel potent H4 R ligands to explore their therapeutic value in allergy, inflammation, autoimmune disorders, and possibly, cancer. Readers will be provided with extensive knowledge on histamine metabolism, as well as cellular histamine transport, storage and release, effects of histamine and histamine receptor ligands, with particular attention to the H4 R, on inflammatory cells including mast cells, basophils, eosinophils, neutrophils, macrophages, dendritic cells, and T cells. The present knowledge on the regulatory role of histamine and the therapeutic exploitation of histamine receptor ligands in atopic diseases, with emphasis on human and animal models of asthma, allergic dermatitis and pruritus are discussed.

Mode of access: Internet via World Wide Web.

This eBook is made available Open Access. Unless otherwise specified individually in the content, the work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND) license:

https://creativecommons.org/licenses/by-nc-nd/3.0

https://www.degruyter.com/dg/page/open-access-policy

In English.

Description based on online resource; title from PDF title page (publisher's Web site, viewed 02. Feb 2021)